Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells

Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Israeli Patent Office has granted a notice of allowance for a patent application covering Allocetra^TM, an immunotherapy product targeting various diseases, including sepsis and COVID-19. This patent will provide intellectual property protection in Israel until at least 2037. Allocetra^TM is designed to reprogram macrophages to restore their homeostatic state, potentially offering new treatment options for life-threatening conditions. The patent issuance is expected in Q1 2022.

Positive

• Issuance of a patent for Allocetra^TM could strengthen market position and protect intellectual property until at least 2037.
• Allocetra^TM aims to address critical unmet medical needs in treating sepsis and COVID-19.

Negative

• None.

Nes-Ziona, Israel, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Israeli Patent Office issued a notice of allowance for a new patent application (number 255119) covering Allocetra^TM, the Company’s immunotherapy product candidate. Upon issuance, the patent will provide added intellectual property protection in Israel through at least 2037, with claims covering the use of pooled donor cells as source materials for Allocetra^TM. The Company expects that this new Israeli patent will be issued in the first quarter of 2022.

Enlivex is developing Allocetra^TM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra^TM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with other therapeutic agents.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra^TM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT                                                                            
Shachar Shlosberger, CFO                                                                    
Enlivex Therapeutics, Ltd.                                                                      
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

FAQ

What is the significance of the patent allowance for Allocetra^TM by Enlivex?

The patent allowance provides Enlivex with intellectual property protection in Israel until at least 2037, enhancing their competitive position.

What diseases does Allocetra^TM target?

Allocetra^TM targets sepsis, COVID-19, and solid tumors by reprogramming macrophages.

When is the patent for Allocetra^TM expected to be issued?

The patent is expected to be issued in the first quarter of 2022.

What are the potential benefits of Allocetra^TM?

Allocetra^TM has the potential to provide a novel immunotherapeutic mechanism for life-threatening conditions.